Tags

Type your tag names separated by a space and hit enter

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
J Ren Nutr. 2007 Nov; 17(6):416-22.JR

Abstract

OBJECTIVE

This study was designed to evaluate the efficacy of magnesium carbonate as a phosphate binder in hemodialysis patients.

DESIGN

This study was a prospective, randomized, open-label trial comparing magnesium carbonate/calcium carbonate versus calcium acetate as a sole phosphate binder.

SETTING

This study involved outpatient hemodialysis.

PARTICIPANTS

We recruited 30 stable hemodialysis patients without a history of frequent diarrhea.

INTERVENTION

After receiving informed consent, we randomized patients 2:1 to magnesium carbonate versus calcium acetate. The dose of each binder was titrated to achieve the Kidney Disease Outcomes Quality Initiative (K/DOQI) phosphate target of <5.5 mg/dL.

MAIN OUTCOME MEASURE

The efficacy-phase serum phosphorus concentration and the percentage of patients meeting K-DOQI targets for phosphorus, along with the daily elemental calcium intake, were the primary outcome measures.

RESULTS

Magnesium carbonate provided equal control of serum phosphorus (70.6% of the magnebind group and 62.5% of the calcium acetate group had their average serum phosphorus within the K-DOQI target during the efficacy phase), while significantly reducing daily elemental calcium ingestion from phosphate binders (908 +/- 24 vs. 1743 +/- 37 mg/day, P < .0001).

CONCLUSION

Magnesium carbonate was generally well-tolerated in this selected patient population, and was effective in controlling serum phosphorus while reducing elemental calcium ingestion.

Authors+Show Affiliations

University of Colorado Health Sciences Center, Denver, Colorado, USA. david.spiegel@uchsc.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17971314

Citation

Spiegel, David M., et al. "Magnesium Carbonate Is an Effective Phosphate Binder for Chronic Hemodialysis Patients: a Pilot Study." Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, vol. 17, no. 6, 2007, pp. 416-22.
Spiegel DM, Farmer B, Smits G, et al. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr. 2007;17(6):416-22.
Spiegel, D. M., Farmer, B., Smits, G., & Chonchol, M. (2007). Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, 17(6), 416-22.
Spiegel DM, et al. Magnesium Carbonate Is an Effective Phosphate Binder for Chronic Hemodialysis Patients: a Pilot Study. J Ren Nutr. 2007;17(6):416-22. PubMed PMID: 17971314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. AU - Spiegel,David M, AU - Farmer,Beverly, AU - Smits,Gerard, AU - Chonchol,Michel, PY - 2007/04/25/received PY - 2007/11/1/pubmed PY - 2007/12/6/medline PY - 2007/11/1/entrez SP - 416 EP - 22 JF - Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation JO - J Ren Nutr VL - 17 IS - 6 N2 - OBJECTIVE: This study was designed to evaluate the efficacy of magnesium carbonate as a phosphate binder in hemodialysis patients. DESIGN: This study was a prospective, randomized, open-label trial comparing magnesium carbonate/calcium carbonate versus calcium acetate as a sole phosphate binder. SETTING: This study involved outpatient hemodialysis. PARTICIPANTS: We recruited 30 stable hemodialysis patients without a history of frequent diarrhea. INTERVENTION: After receiving informed consent, we randomized patients 2:1 to magnesium carbonate versus calcium acetate. The dose of each binder was titrated to achieve the Kidney Disease Outcomes Quality Initiative (K/DOQI) phosphate target of <5.5 mg/dL. MAIN OUTCOME MEASURE: The efficacy-phase serum phosphorus concentration and the percentage of patients meeting K-DOQI targets for phosphorus, along with the daily elemental calcium intake, were the primary outcome measures. RESULTS: Magnesium carbonate provided equal control of serum phosphorus (70.6% of the magnebind group and 62.5% of the calcium acetate group had their average serum phosphorus within the K-DOQI target during the efficacy phase), while significantly reducing daily elemental calcium ingestion from phosphate binders (908 +/- 24 vs. 1743 +/- 37 mg/day, P < .0001). CONCLUSION: Magnesium carbonate was generally well-tolerated in this selected patient population, and was effective in controlling serum phosphorus while reducing elemental calcium ingestion. SN - 1532-8503 UR - https://www.unboundmedicine.com/medline/citation/17971314/Magnesium_carbonate_is_an_effective_phosphate_binder_for_chronic_hemodialysis_patients:_a_pilot_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1051-2276(07)00181-1 DB - PRIME DP - Unbound Medicine ER -